全文获取类型
收费全文 | 41103篇 |
免费 | 2494篇 |
国内免费 | 217篇 |
专业分类
耳鼻咽喉 | 467篇 |
儿科学 | 1292篇 |
妇产科学 | 1191篇 |
基础医学 | 4123篇 |
口腔科学 | 1319篇 |
临床医学 | 3520篇 |
内科学 | 8857篇 |
皮肤病学 | 853篇 |
神经病学 | 2359篇 |
特种医学 | 1497篇 |
外国民族医学 | 9篇 |
外科学 | 7504篇 |
综合类 | 943篇 |
现状与发展 | 3篇 |
一般理论 | 28篇 |
预防医学 | 2771篇 |
眼科学 | 1406篇 |
药学 | 3224篇 |
1篇 | |
中国医学 | 289篇 |
肿瘤学 | 2158篇 |
出版年
2023年 | 434篇 |
2022年 | 1142篇 |
2021年 | 1791篇 |
2020年 | 1088篇 |
2019年 | 1435篇 |
2018年 | 1765篇 |
2017年 | 1290篇 |
2016年 | 1377篇 |
2015年 | 1514篇 |
2014年 | 1890篇 |
2013年 | 2298篇 |
2012年 | 3377篇 |
2011年 | 3271篇 |
2010年 | 1887篇 |
2009年 | 1625篇 |
2008年 | 2379篇 |
2007年 | 2474篇 |
2006年 | 2193篇 |
2005年 | 1944篇 |
2004年 | 1760篇 |
2003年 | 1472篇 |
2002年 | 1304篇 |
2001年 | 403篇 |
2000年 | 345篇 |
1999年 | 327篇 |
1998年 | 228篇 |
1997年 | 156篇 |
1996年 | 162篇 |
1995年 | 129篇 |
1994年 | 117篇 |
1993年 | 93篇 |
1992年 | 188篇 |
1991年 | 184篇 |
1990年 | 159篇 |
1989年 | 144篇 |
1988年 | 141篇 |
1987年 | 121篇 |
1986年 | 108篇 |
1985年 | 147篇 |
1984年 | 90篇 |
1983年 | 63篇 |
1982年 | 68篇 |
1981年 | 65篇 |
1980年 | 55篇 |
1979年 | 69篇 |
1978年 | 52篇 |
1977年 | 43篇 |
1976年 | 46篇 |
1974年 | 44篇 |
1973年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
996.
Risk factors for hospital admission among COVID-19 patients with diabetes: A study from Saudi Arabia
Ayman A. Al Hayek Asirvatham A. Robert Abdullah Bin Matar Ali Algarni Haneen Alkubedan Turki Alharbi Afrah Al Amro Seham A. Alrashidi Mohamed Al Dawish 《Saudi medical journal》2020,41(10):1090
Objectives:To elucidate the risk factors for hospital admission among COVID-19 patients with type 2 diabetes mellitus (T2DM).Methods:This retrospective study was conducted at the Prince Sultan Military Medical City, Riyadh, Saudi Arabia between May 2020 and July 2020. Out of 7,260 COVID-19 patients, 920 were identified as T2DM. After the exclusion process, 806 patients with T2DM were included in this analysis. Patients’ data were extracted from electronic medical records. A logistic regression model was performed to estimate the risk factors of hospital admission.Results:Of the total of 806 COVID-19 patients with T2DM, 48% were admitted in the hospital, 52% were placed under home isolation. Older age between 70-79 years (OR [odd ratio] 2.56; p=0.017), ≥80 years (OR 6.48; p=0.001) were significantly more likely to be hospitalized compared to <40 years. Similarly, patients with higher HbA1c level of ≥9% compared to <7%; (OR 1.58; p=0.047); patients with comorbidities such as, hypertension (OR 1.43; p=0.048), cardiovascular disease (OR 1.56; p=0.033), cerebrovascular disease (OR 2.38; p=0.016), chronic pulmonary disease (OR 1.51; p=0.018), malignancy (OR 2.45; p=0.025), chronic kidney disease (CKD) IIIa, IIIb, IV (OR 2.37; p=0.008), CKD V (OR 5.07; p=0.007) were significantly more likely to be hospitalized. Likewise, insulin-treated (OR 1.46; p=0.03) were more likely to require hospital admission compared to non-insulin treated patients.Conclusion:Among COVID-19 patients with diabetes, higher age, high HbA1c level, and presence of other comorbidities were found to be significant risk factors for the hospital admission. 相似文献
997.
Mithat Büyük?elik Mehmet Keskin ?zlem Keskin Ali Bay Beltinge Demircio?lu K?l?? Y?lmaz Kor M. Arda K?l?n? Ay?e Balat 《Journal of clinical research in pediatric endocrinology》2014,6(1):47-50
Autoimmune polyglandular syndrome (APS) is a disorder which is associated with multiple endocrine gland insufficiency and also with non-endocrine manifestations. The pathophysiology of APS is poorly understood, but the hallmark evidence of APS is development of autoantibodies against multiple endocrine and non-endocrine organs. These autoantibodies are responsible for the dysfunction of the affected organs and sometimes may also cause non-endocrine organ dysfunction. The hemolytic-uremic syndrome (HUS) is a serious and life-threatening disease which develops due to many etiological factors including autoimmune disorders. Here, we present an unusual case of APS. Ectodermal dysplasia with immune deficiency and HUS occurred concomitantly in the same patient with APS type 3c. Once the autoantibody generation was initiated in the human body, development of multiple disorders due to organ dysfunction and also autoantibody-related diseases may have occurred. 相似文献
998.
Ryan M Thomas Thomas A Aloia Mark J Truty Warren H Tseng Eugene A Choi Steven A Curley Jean N Vauthey Eddie K Abdalla 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2014,16(7):677-685
Background
The biology of hepatic epithelial haemangioendothelioma (HEHE) is variable, lying intermediate to haemangioma and angiosarcoma. Treatments vary owing to the rarity of the disease and frequent misdiagnosis.Methods
Between 1989 and 2013, patients retrospectively identified with HEHE from a single academic cancer centre were analysed to evaluate clinicopathological factors and initial treatment regimens associated with survival.Results
Fifty patients with confirmed HEHE had a median follow-up of 51 months (range 1–322). There was no difference in 5-year survival between patients presenting with unilateral compared with bilateral hepatic disease (51.4% versus 80.7%, respectively; P = 0.1), localized compared with metastatic disease (69% versus 78.3%, respectively; P = 0.7) or an initial treatment regimen of Surgery, Chemotherapy/Embolization or Observation alone (83.3% versus 71.3% versus 72.4%, respectively; P = 0.9). However, 5-year survival for patients treated with chemotherapy at any point during their disease course was decreased compared with those who did not receive any chemotherapy (43.6% versus 82.9%, respectively; P = 0.02) and was predictive of a decreased overall survival on univariate analysis [HR 3.1 (CI 0.9–10.7), P = 0.02].Conclusions
HEHE frequently follows an indolent course, suggesting that immediate treatment may not be the optimal strategy. Initial observation to assess disease behaviour may better stratify treatment options, reserving surgery for those who remain resectable/transplantable. Prospective cooperative trials or registries may confirm this strategy. 相似文献999.
Ronald A. Booth Stephen A. Hill Andrew Don-Wauchope P. Lina Santaguida Mark Oremus Robert McKelvie Cynthia Balion Judy A. Brown Usman Ali Amy Bustamam Nazmul Sohel Parminder Raina 《Heart failure reviews》2014,19(4):439-451
National and international guidelines have been published recommending the use of natriuretic peptides as an aid to the diagnosis of heart failure (HF) in acute settings; however, few specific recommendations exist for governing the use of these peptides in primary care populations. To summarize the available data relevant to the diagnosis of HF in primary care patient population, we systematically reviewed the literature to identify original articles that investigated the diagnostic accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) in primary care settings. The search yielded 25,864 articles in total: 12 investigating BNP and 20 investigating NT-proBNP were relevant to our objective and included in the review. QUADAS-2 and GRADE were used to assess the quality of the included articles. Diagnostic data were pooled based on three cutpoints: lowest and optimal, as chosen by study authors, and manufacturers’ suggested. The effect of various determinants (e.g., age, gender, BMI, and renal function) on diagnostic performance was also investigated. Pooled sensitivity and specificity of BNP and NT-proBNP using the lowest [0.85 (sensitivity) and 0.54 (specificity)], optimal (0.80 and 0.61), and manufacturers’ (0.74 and 0.67) cutpoints showed good performance for diagnosing HF. Similar performance was seen for NT-proBNP: lowest (0.90 and 0.50), optimal (0.86 and 0.58), and manufacturers’ (0.82 and 0.58) cutpoints. Overall, we rated the strength of evidence as high because further studies will be unlikely to change the estimates diagnostic performance. 相似文献
1000.
Pasqualina L. Santaguida Andrew C. Don-Wauchope Usman Ali Mark Oremus Judy A. Brown Amy Bustamam Stephen A. Hill Ronald A. Booth Nazmul Sohel Robert McKelvie Cynthia Balion Parminder Raina 《Heart failure reviews》2014,19(4):507-519
The aim of this systematic review was to determine whether B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) independently add incremental value for predicting mortality and morbidity in patients with acute decompensated heart failure (ADHF). Medline®, Embase?, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL were searched from 1989 to June 2012. We also searched reference lists of included articles, systematic reviews, and the gray literature. Studies were screened for eligibility criteria and assessed for risk of bias. Data were extracted on study design, population demographics, assay cutpoints, prognostic risk prediction model covariates, statistical methods, outcomes, and results. From 183 citations, only seven studies (5 BNP and 2 NT-proBNP) considered incremental value in ADHF subjects admitted to acute care centers. Admission assay levels and length of follow-up varied for BNP studies (31 days to 12 months) and for NT-proBNP studies (25–82 months). All studies presented at least one estimate of incremental value of BNP/NT-proBNP relative to the base prognostic model. Using discrimination or likelihood statistics, these studies consistently showed that BNP or NT-proBNP increased model performance. Three studies used reclassification and model validation computations to establish incremental value; these studies showed less consistency with respect to added value. In conclusion, the literature assessing incremental value of BNP/NT-proBNP in ADHF populations is limited to seven studies evaluating only mortality outcomes and at moderate risk of bias. Although there were differences in the base risk prediction models, assay cutpoints, and lengths of follow-up, there was consistency in BNP/NT-proBNP adding incremental value in prediction models in ADHF patients. 相似文献